S
Stephen M. Hahn
Researcher at University of Texas MD Anderson Cancer Center
Publications - 114
Citations - 8252
Stephen M. Hahn is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Radiation therapy & Lung cancer. The author has an hindex of 30, co-authored 114 publications receiving 6847 citations. Previous affiliations of Stephen M. Hahn include Food and Drug Administration & Hospital of the University of Pennsylvania.
Papers
More filters
CA : A Cancer Journal for Clinicians
Patrizia Agostinis,Kristian Berg,Keith A. Cengel,Thomas H. Foster,Albert W. Girotti,Sandra O. Gollnick,Stephen M. Hahn,Michael R. Hamblin,Asta Juzeniene,David Kessel,Mladen Korbelik,Johan Moan,Pawel Mroz,Dominika Nowis,Jacques Piette,Brian C. Wilson,Jakub Golab +16 more
Journal ArticleDOI
Improving immune-vascular crosstalk for cancer immunotherapy
TL;DR: It is proposed that the reciprocal regulation between tumour vascular normalization and immune reprogramming forms a reinforcing loop that reconditions the tumour immune microenvironment to induce durable antitumour immunity.
Journal Article
Tempol, a Stable Free Radical, Is a Novel Murine Radiation Protector
Stephen M. Hahn,Zelig Tochner,C M Krishna,Joseph Glass,L Wilson,Ayelet M. Samuni,M. Sprague,David Venzon,Eli Glatstein,James Mitchell +9 more
TL;DR: Tempol represents a new class of in vivo, non-sulfur-containing radiation protectors and has the potential for hypoxic radiosensitization and aerobic cell radioprotection, and Temporal or other analogues may have potential therapeutic application.
Journal ArticleDOI
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Xiaohong Wang,Jonathan E. Schoenhals,Ailin Li,David Valdecanas,Huiping Ye,Fenglin Zang,Chad Tang,Ming Tang,Chang Gong Liu,Xiuping Liu,Sunil Krishnan,James P. Allison,Padmanee Sharma,Patrick Hwu,Ritsuko Komaki,Willem W. Overwijk,Daniel R. Gomez,Joe Y. Chang,Stephen M. Hahn,Maria Angelica Cortez,James W. Welsh +20 more
TL;DR: Localized radiotherapy induced IFNβ production, thereby elevating MHC class I expression on both parental and resistant tumor cells and restoring the responsiveness of resistant tumors to anti-PD-1 therapy, and adjuvant radiotherapy can overcome resistance.
Journal ArticleDOI
Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.
Quynh-Nhu Nguyen,Stephen G. Chun,Edward Chow,Ritsuko Komaki,Zhongxing Liao,Rensi Zacharia,Bill K. Szeto,James W. Welsh,Stephen M. Hahn,C. David Fuller,Bryan S. Moon,Justin E. Bird,Robert L. Satcher,Patrick P. Lin,Melenda Jeter,Michael S. O'Reilly,Valerae O. Lewis +16 more
TL;DR: Delivering high-dose, single-fraction SBRT seems to be an effective treatment option for patients with painful bone metastases and should be considered for patients expected to have relatively long survival.